Labeling Requirements for Human Prescription Drug and Biological Products
Revision of a currently approved collection
No
Regular
12/23/2021
Requested
Previously Approved
36 Months From Approved
01/31/2022
432,929
541
1,912,106
1,258,907
0
0
The information collection supports agency regulations governing the content and format of labeling for human prescription drug and biological products. Respondents to the collection are sponsors of new drug and biological product applications.
The information collection reflects changes and adjustments. We are accounting for burden that may be associated with requirements found in 21 CFR § 201.328 applicable to the labeling of medical gas containers not previously included. This results in an overall increase to the collection by 432,388 responses and 653,199 hours annually.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.